Fortunes diverge for solo drug launchers
A solo drug launch is a testing time for a small company, made even tougher by the pandemic.
Biocryst looks to raise the profile of its factor D inhibitor
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Apellis takes the complement fight to Astrazeneca
The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
First-quarter catalysts for the smaller players
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
